Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1400029
European Journal of Endocrinology, Vol 140, Issue 1, 29-34
Copyright © 1999 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huet, F
Right arrow Articles by Chaussain, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huet, F
Right arrow Articles by Chaussain, J.
Clinical Studies

Long-term results of GH therapy in GH-deficient children treated before 1 year of age

F Huet, JC Carel, JL Nivelon, and JL Chaussain

Service de Pediatrie 1, Hopital d'Enfants, Dijon, France.

OBJECTIVES: To evaluate the long-term effects of GH therapy in early diagnosed GH-deficient patients treated before 1 year of age. Study design: We studied all 59 patients (33 males) recorded by Association France-Hypophyse and treated with GH (0.50+/-0.15 IU/kg (S.D.) per week) before 1 year of age. Clinical presentation and growth parameters under GH treatment were analyzed. RESULTS: Neonatal manifestations of hypopituitarism were frequent: hypoglycemia (n=50), jaundice (n=25) and micropenis (n=17/33). Although birth length was moderately reduced (-0.9+/-1.4), growth retardation at diagnosis (5.8+/-3.8 months) was severe (-3.5+/-1.9 standard deviation scores (SDS)). Fifty patients (85%) had thyrotropin and/or corticotropin deficiency. After a mean duration of GH therapy of 8.0+/-3.6 years, change in height SDS was +3.11+/-2.06 S.D., exceeding 4 SDS in 19 patients. Only 9 patients (15%) did not reach a height of -2 S.D. for chronological age and 20 patients (34%) exceeded their target height. Pretreatment height SDS was independently associated with total catch-up growth. CONCLUSION: Conventional doses of GH allow normalization of height in patients with early GH deficiency and treatment.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
E. O. Reiter, D. A. Price, P. Wilton, K. Albertsson-Wikland, and M. B. Ranke
Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International Database
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2047 - 2054.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. B. Ranke, A. Lindberg, K. Albertsson-Wikland, P. Wilton, D. A. Price, E. O. Reiter, and on behalf of the KIGS International Board
Increased Response, But Lower Responsiveness, to Growth Hormone (GH) in Very Young Children (Aged 0-3 Years) with Idiopathic GH Deficiency: Analysis of Data from KIGS
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1966 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Vallette-Kasic, T. Brue, A.-M. Pulichino, M. Gueydan, A. Barlier, M. David, M. Nicolino, G. Malpuech, P. Dechelotte, C. Deal, et al.
Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained by TPIT Gene Mutations
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1323 - 1331.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 European Society of Endocrinology.